
zortress
Pharmaranks rates Zortress 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Zortress (Everolimus) is a kinase inhibitor.
Everolimus · by Novartis
Available as a generic: Everolimus
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Everolimus
- Drug class
- Kinase Inhibitor
- Form
- Tablet
- Strength
- Everolimus 0.25MG · Everolimus 0.5MG · Everolimus 0.75MG · Everolimus 1MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Novartis
- Half-life
- about 30 hours (mean terminal elimination half-life) (how long it stays in your system)
- What the pharmacy pays
- ~$219.28 for 30 — not your price
- FDA application
- NDA021560
How long does Everolimus stay in your body?
The elimination half-life of everolimus is about 30 hours (mean terminal elimination half-life) — the time it takes the body to clear about half of it. As a rule of thumb, a medicine is mostly gone after roughly 4 to 5 half-lives, though this varies from person to person with age and kidney or liver function. Not a prodrug; everolimus is the main circulating component in blood. Its six detected metabolites showed roughly 100-times less activity than everolimus itself, so there is no active metabolite that outlasts the parent. The label reports no clinically meaningful change with age or sex, and renal impairment (creatinine clearance 25-178 mL/min) did not significantly affect clearance. Hepatic impairment increases exposure substantially, though: AUC rose about 1.8-, 3.2-, and 3.6-fold in mild, moderate, and severe (Child-Pugh A/B/C) impairment, so the label calls for dose reduction in hepatic impairment.
This is general information, not medical advice. It doesn’t tell you when a drug test would read negative (tests detect substances for different, often longer, windows) or when it’s safe to take another dose — ask your pharmacist or prescriber. Source: Everolimus tablets - DailyMed label, Clinical Pharmacology (12.3).
Drug class
- Kinase Inhibitor
- mTOR Inhibitor Immunosuppressant
How this class works, per Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf.
Dosage forms
Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- How does Zortress work?
- Zortress is a kinase inhibitor. Kinase inhibitors block protein kinases, the enzymes that relay 'grow and divide' signals inside cells. By shutting down the overactive kinase signals that a tumor depends on, they help slow or stop cancer cells from multiplying.
- How is Zortress rated?
- pharmaranks gives Zortress a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- How much does Zortress cost?
- Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $219.28 for 30, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins.
- Is there a coupon or discount for Zortress?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Zortress. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Zortress?
- Zortress is marketed by Novartis. You can see Novartis's full profile, rating, and other products on pharmaranks.
- Is Zortress a brand-name or generic drug?
- Zortress is a brand-name product with the active ingredient Everolimus. Lower-cost generic equivalents containing Everolimus are available — ask your pharmacist.
- Is Zortress available over the counter?
- No. Zortress is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Zortress come in?
- Zortress is currently marketed as tablet, per the FDA's National Drug Code Directory.
- What class of drug is Zortress?
- Zortress is classified as kinase inhibitor, mtor inhibitor immunosuppressant, per the FDA's Established Pharmacologic Class.
- Is Zortress FDA-registered?
- Zortress is on record with the U.S. FDA under application number NDA021560. You can verify this on its official FDA label.
- Has Zortress been recalled by the FDA?
- Zortress has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Zortress safe?
- There's no single safe-or-not verdict. pharmaranks gives Zortress a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about EVEROLIMUS
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 17,188 reports naming EVEROLIMUS — the active ingredient in Zortress, and the FDA flagged 89% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- malignant neoplasm progression1,553 reports
- diarrhoea1,234 reports
- fatigue873 reports
- nausea797 reports
- dyspnoea680 reports
- pyrexia644 reports
- vomiting638 reports
- pneumonia617 reports
Read these as a signal, not a rate. A report does not mean EVEROLIMUS caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
danziten
Nilotinib Tartrate
everolimus
Everolimus
ofev
Nintedanib Esylate
sprycel
Dasatinib
afinitor
Everolimus
calquence
Acalabrutinib
Compare Zortress head-to-head
More kinase inhibitor drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
zortress
70/100